Shares of United States Antimony Corporation (UAMY) plummeted 5.12% in intraday trading on Thursday, following the release of its third-quarter financial results that fell short of expectations. The company also provided a fiscal year 2025 sales forecast that came in below analyst estimates, further contributing to the stock's decline.
United States Antimony reported a third-quarter loss of 4 cents per share, missing the consensus estimate for positive earnings of 2 cents per share. Revenue for the quarter came in at $8.70 million, significantly below the expected $12.86 million. Adding to investors' concerns, the company issued a fiscal year 2025 sales outlook ranging between $40 million and $43 million, which falls short of the $46.38 million consensus estimate.
Despite the negative market reaction, there were some positive developments for the company. U.S. Antimony highlighted substantial year-to-date growth in its broader operations, including higher revenue and gross profit for the first nine months of 2025. The company also secured two major sales contracts: a five-year Defense Logistics Agency IDIQ contract valued at up to $245 million and a five-year commercial supply agreement worth approximately $107 million. Additionally, H.C. Wainwright raised its target price for UAMY to $10.25 from $8.5, suggesting potential long-term confidence in the company despite the current setback. As the market digests this mixed information, investors will be closely watching United States Antimony's ability to overcome its near-term challenges and capitalize on its future opportunities.
Comments